Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

20191,828 citationsJournal Articlebronze Open Access

Authors

Mansoor Husain · Ted Rogers Centre for Heart Research

Andreas L. Birkenfeld · Paul Langerhans Institute Dresden

Morten Donsmark · Novo Nordisk (Denmark)

Kathleen Dungan · The Ohio State University

Freddy G. Eliaschewitz · DASA (Brazil)

Denise Reis Franco · DASA (Brazil)

Ole Kleist Jeppesen

Abstract

Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 9, pp. 841-851

DOI: 10.1056/nejmoa1901118

Field-Weighted Citation Impact: 140.59